Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis

  • Technology appraisal guidance
  • TA276
  • Published: 

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: Economic analysis of updated Patient Access Scheme prepared by School of Health and Related Research (ScHARR)

This page was last updated: 23 January 2013